UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) June 30, 2010
 
NEPHROS, INC.
(Exact name of registrant as specified in its charter)

Delaware
 (State or other jurisdiction of incorporation)

 
001-32288
  
13-3971809
  
 
(Commission File Number)
  
(IRS Employer ID Number)
  

 
41 Grand Avenue, River Edge, New Jersey
07661
  
 
(Address of principal executive offices)
 (Zip Code)
  

Registrant's telephone number, including area code (201) 343-5202


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act   (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

Item 8.01.  Other Events.
 
On July 7, 2010, Nephros, Inc. issued a press release announcing that it received a formal response from the FDA regarding the Company’s 510(k) application for its Hemodiafiltration System.  A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
 
 
Item 9.01. Financial Statements and Exhibits.

  (d)  Exhibits
     
 
Exhibit No.
Description
     
  99.1
Press release dated July 7, 2010.

2
 
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  Nephros, Inc.  
       
Dated:  July 7, 2010
By:
/s/ Gerald J. Kochanski  
    Gerald J. Kochanski  
   
Chief Financial Officer
  

3